FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesForecasting
Topics: EAP, Forecasting / Planning
Video
Members
EAP 103: Expanded Access Module 3 Supply Planning
Topics: Additional Concepts, Closeout, EAP, Execution, Forecasting / Planning
Presentation
Members
GDPR Considerations for DtP Supply Chains
Topics: Regulatory, Supply Chain
Guidance Document
Free
